BIAF Stock — bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. (BIAF)

Updated October 16, 2026.

BIAF is a Stock. Total return is -99.9% over the past 4.1 years, 203.5 points behind SPY at 103.6%.

bioAffinity Technologies develops non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other lung diseases using flow cytometry technology; its primary offering, CyPath lung, analyzes sputum samples to identify cancer-related cells. The company operates through diagnostic research and development and laboratory services segments, with ongoing collaborations to evaluate tests for inflammatory biomarkers in asthma and chronic obstructive pulmonary disease. Distribution information is not currently available for this equity security.

BIAF performance versus SPY

Price and return data through 2026-10-16.

Total return is -99.9% over the past 4.1 years, 203.5 points behind SPY at 103.6%. Over the past year its total return — price change plus distributions reinvested — is -92.7%. Its deepest 1-year drawdown was 95.0%.

BIAF key facts

Asset type

Stock

Asset class

Equity

Inception date

09/01/2022

Distribution frequency

None

Last close

$3.73 (as of 2026-10-16)

Market cap

$4,786,224

Average volume

100452.0

Beta

-1.254

Payout ratio

0.0%

EPS

$-109.35

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BIAF risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 95.0%.

Who may consider BIAF — and who may not

It is a weaker fit for investors who need monthly cash flow (BIAF does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on BIAF

• All tickers starting with B

Tagged: Healthcare.

Frequently asked questions